Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Tarsus Pharmaceuticals Inc increased its cash reserves by 213.91%, or 153.29m. Cash Flow from Investing totalled 140.60m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 117.49m for operations while cash generated from financing totalled 130.18m.
Cash flow per share | -3.68 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 6.22 |
---|---|
Tangible book value per share | 5.99 |
More ▼
Balance sheet in USDView more
Current ratio | 5.42 |
---|---|
Quick ratio | 5.38 |
Total debt/total equity | 0.302 |
---|---|
Total debt/total capital | 0.2319 |
More ▼